Testing effectiveness (Phase 2)UnknownNCT02825836
What this trial is testing
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Who this might be right for
Relapsed/Refractory B Cell MalignanciesMantle Cell Lymphoma and Diffuse Large B Cell LymphomaChronic Lymphocytic Leukemia+2 more
Telios Pharma, Inc. 130